HASPIN and breast carcinoma: The results showed that there are 593 breast cancer samples (57.1%) containing heterozygous deletion of the GSG2 gene, however, there is a very low frequency of GSG2 gene amplification (< 1%) and GSG2 gene gain (< 7%) in breast cancer samples (Figure 4a).